caa a22 4500 469118563 CHVBK 20180323133131.0 cr unu---uuuuu 170328e19921101xx s 000 0 eng 10.1007/BF02245874 doi (NATIONALLICENCE)springer-10.1007/BF02245874 Different capability of n -methyl- d -aspartate antagonists to elicit EEG and behavioural phencyclidine-like effects in rats [Elektronische Daten] [S. Sagratella, A. Pezzola, P. Popoli, A. de Carolis] Phencyclidine (PCP), a drug inducing schizophrenia-like symptoms in humans, is reported to be a noncompetitive antagonist at the N-methyl-d-aspartate (NMDA) subtype of excitatory amino acid receptors. In rats, PCP produces three dose-dependent stages of EEG patterns: 1) increase of cortical desynchronization duration; 2) increase of the amplitude of the high-frequency (20-30 Hz) low-voltage (30-50 µV) cortical background activity; 3) appearance of cortical slow (2-3 Hz) wavesharp wave complexes. These EEG changes are accompanied by stimulatory-depressive effects such as stereotypy (circling, head weaving) and ataxia. In the present study, the EEG and behavioural effects induced by systemic administration of the NMDA antagonists dizocilpine (MK 801), dextromethorphan (DM), [+ -alpha-(4-chlorophenyl)-4-[(phenyl)methyl-1-piperidine ethanol] (SL 82.0715), (+)3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP), cis-4-phosphonomethyl-2-piperidine-carboxylic acid (CGS 19755) have been compared to those of PCP in rats. The rank of potency for inducing PCP-like EEG stages 1-3 was as follows: MK 801 > PCP > CGS 19755 > CPP. These drugs also induced PCP-like behavioural effects. On the contrary, DM and SL 82.0715, administered up to the dose of 100 mg/kg IP, failed to induce PCP-like behavioural effects and elicited only the stage 1 of PCP-like EEG. These results strongly suggest the involvement of NMDA neurotransmission in the behavioural and EEG effects of PCP. Springer-Verlag, 1992 NMDA nationallicence PCP nationallicence EEG nationallicence Behaviour nationallicence Rats nationallicence Sagratella S. Pharmacology Department, Istituto Superiore di Sanita, Viale Regina Elena 299, I-00161, Roma, Italy aut Pezzola A. Pharmacology Department, Istituto Superiore di Sanita, Viale Regina Elena 299, I-00161, Roma, Italy aut Popoli P. Pharmacology Department, Istituto Superiore di Sanita, Viale Regina Elena 299, I-00161, Roma, Italy aut de Carolis A. Pharmacology Department, Istituto Superiore di Sanita, Viale Regina Elena 299, I-00161, Roma, Italy aut Psychopharmacology Springer-Verlag 109/3(1992-11-01), 277-282 0033-3158 109:3<277 1992 109 213 https://doi.org/10.1007/BF02245874 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245874 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sagratella S. Pharmacology Department, Istituto Superiore di Sanita, Viale Regina Elena 299, I-00161, Roma, Italy aut NATIONALLICENCE 700 1- Pezzola A. Pharmacology Department, Istituto Superiore di Sanita, Viale Regina Elena 299, I-00161, Roma, Italy aut NATIONALLICENCE 700 1- Popoli P. Pharmacology Department, Istituto Superiore di Sanita, Viale Regina Elena 299, I-00161, Roma, Italy aut NATIONALLICENCE 700 1- de Carolis A. Pharmacology Department, Istituto Superiore di Sanita, Viale Regina Elena 299, I-00161, Roma, Italy aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 109/3(1992-11-01), 277-282 0033-3158 109:3<277 1992 109 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer